Verrica制药 2026年季度报告

FORM 10-Q______________________________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from ____ to _____Commission File Number: 001-38529______________________________________________________ Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter)______________________________________________________ (I.R.S. EmployerIdentification No.) Registrant’s telephone number, including area code: (484) 453-3300N/A(Former name, former address and former fiscal year, if changed since last report) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subjectto such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo As of May5, 2026, the registrant had 17,178,786 shares of common stock, $0.0001 par value per share, outstanding. VERRICA PHARMACEUTICALS INC.QUARTERLY REPORT ON FORM 10-QTABLE OF CONTENTS PART I. FINANCIAL INFORMATION Item 1.Consolidated Financial Statements (Unaudited)1Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations20Item 3.Quantitative and Qualitative Disclosures About Market Risks28Item 4.Controls and Procedures28 PART I. FINANCIAL INFORMATION VERRICA PHARMACEUTICALS INC.CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except share and per share amounts) (Unaudited) VERRICA PHARMACEUTICALS INC.CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)(in thousands, except share amounts)(Unaudited) VERRICA PHARMACEUTICALS INC.CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)(Unaudited) VERRICA PHARMACEUTICALS INC.CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)(Unaudited) VERRICA PHARMACEUTICALS INC.Notes to Consolidated Financial Statements(Unaudited) Note 1—Organization and Description of Business Operations Verrica Pharmaceuticals Inc. (the "Company") was formed on July 3, 2013 and is incorporated in the State of Delaware. TheCompany is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases,including skin cancers. On July 21, 2023, the U.S. Food and Drug Administration ("FDA") approved YCANTH (VP-102) topicalsolution for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. During the threemonths ended March 31, 2026, the Company formed a wholly owned subsidiary in Ireland to facilitate regulatory filings in theEuropean Union. The subsidiary had no material operations during the period. Reverse Stock Split At the close of trading on July24, 2025, the Company effected a reverse stock split at a ratio of 1-for-10 shares of itscommon stock. As a result, every ten shares of the Company’s issued and outstanding common stock were automatically combinedinto one share. The reverse stock split affected all stockholders uniformly and did not alter any stockholder’s percentage ownershipinterest in the Company. No fractional shares were issued as a result of the reverse stock split and the split did not impact the par value of theCompany's common stock. Any fractional shares that would otherwise have resulted from the reverse stock split were rounded downto the next whole share. The accompanying consolidated financial statements and footnotes have been adjusted to reflect the impact of the reversestock split as though it had occurred in all periods presented. Liquidity and Capital Resources The Company has incurred substantial operating losses since inception and expects to continue to incur significant losses forthe foreseeable fut